Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

A Cleveland Clinic-led team of scientists and physicians has discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T cells during immunotherapy and resist treatment.

Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma. This is an ASCO Meeting Abstract ...

Researchers at the Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, reported on the development of a new type of nanomedicine called antibody-conjugated ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine ...

Our immune system guards against cancer development by constantly surveilling the body and eliminating unhealthy cells. Immune cells are highly suspicious of other cells. While this leads to a swift ...

The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on ...